272 related articles for article (PubMed ID: 24721970)
1. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
2. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
4. Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
Matsumoto K; Ikeda M; Matsumoto T; Nagashio R; Nishimori T; Tomonaga T; Nomura F; Sato Y; Kitasato H; Iwamura M
Asian Pac J Cancer Prev; 2014; 15(22):9927-31. PubMed ID: 25520130
[TBL] [Abstract][Full Text] [Related]
5. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
6. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
7. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
8. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
9. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer.
Kim YH; Yan C; Lee IS; Piao XM; Byun YJ; Jeong P; Kim WT; Yun SJ; Kim WJ
Investig Clin Urol; 2016 Mar; 57(2):106-12. PubMed ID: 26981592
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach.
Huang Z; Lin L; Gao Y; Chen Y; Yan X; Xing J; Hang W
Mol Cell Proteomics; 2011 Oct; 10(10):M111.007922. PubMed ID: 21799048
[TBL] [Abstract][Full Text] [Related]
11. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
12. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
13. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
15. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
16. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
17. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
18. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
19. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Zhan Y; Du L; Wang L; Jiang X; Zhang S; Li J; Yan K; Duan W; Zhao Y; Wang L; Wang Y; Wang C
Mol Cancer; 2018 Sep; 17(1):142. PubMed ID: 30268126
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
